Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody expressing mesoCAR-T in advanced solid tumors
NCT03615313Phase 2Unknown
- Start
- Aug 2018
- Primary completion
- Aug 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-programmed cell death protein 1 mesothelin-targeted chimeric antigen receptor T-cells in solid tumor, malignant mesothelioma, pancreatic cancer (PC) and 4 more. Primary endpoint: Incidence of treatment-related adverse events at 2 years. Status: unknown.
02
Drugs
anti-programmed cell death protein 1 mesothelin-targeted chimeric antigen receptor T-cells
03
Conditions
solid tumormalignant mesotheliomapancreatic cancer (PC)cholangiocarcinoma (CCA)ovarian cancer
Beyond the preview
Go deeper on NCT03615313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615313.